IPO Window Opens as Lockup Flood and Rule Rewrite Reshape Equity Plumbing

The IPO market is having its busiest stretch of 2026, and the pipeline running beneath it is shifting at the same time. Three developments converge this month: a wave of new listings led by Jersey Mike’s $1 billion debut, a staggered lockup expiration at SpaceX that could unleash far more shares than any IPO, and an SEC proposal to rescind the core trade-through protections that have governed U.S. equity trading since 2005. Each matters on its own. Together, they raise a question about whether the market’s plumbing is being rebuilt while the water is rising.

Jersey Mike’s closes the summer’s marquee IPO

Jersey Mike’s Subs (NYSE: JMKE) priced 43.5 million shares at $23.00 on July 29, raising approximately $1 billion at an implied equity value of about $7.3 billion^[1]. Backed by Blackstone and the Abu Dhabi Investment Authority, it ranks as the largest U.S. consumer IPO of the year and one of the biggest restaurant listings in two decades^[1]. The company operates 3,256 stores under a heavily franchised, asset-light model with roughly 47% adjusted EBITDA margins^[1].

The debut was not a clean pop. Shares closed down about 6% on the first day of trading^[1], opening at $21 — below the $23 offer price — before settling lower. That is not unusual for a large sponsor-exit deal; the underwriters’ challenge is absorbing a billion-dollar supply block into a market that may already be digesting other issuance. A first-day decline does not, by itself, signal a broken deal. The historical base rate for IPOs priced above $500 million is that roughly 40–50% trade below offer in the first session, particularly when insider selling is a component of the float. Jersey Mike’s offering included both primary and secondary shares, which adds to that pressure.

The deal closed on July 31^[1].

A biotech trio lines up for August 5–6

While Jersey Mike’s absorbed the consumer spotlight, a cluster of biotech IPOs is queued for the first full week of August:

Sources: StockAnalysis.com IPO calendar^[2]; Renaissance Capital^[3]; Fierce Biotech^[4].

Attovia, a Goldman-backed Phase 1 biotech focused on immune-mediated diseases, filed its S-1 on July 14 and set terms on July 29, seeking up to $212.5 million^[3]. Braveheart Bio is targeting approximately $300 million^[4], while Vogenx, a North Carolina metabolic disease specialist, is the smallest of the three at roughly $75 million at the midpoint^[4]. Collectively the trio could raise more than $500 million^[4].

A biotech cluster is a useful signal. When three early-stage drug developers file within days of each other and all proceed to pricing, it typically means underwriters see demand windows open — not just for one name, but for the sector. That said, the historical base rate for Phase 1 biotech IPOs is not encouraging for first-day returns. These are companies with limited clinical data, and the IPO is essentially a financing event for pipeline advancement rather than a liquidity event for insiders. The risk profile is asymmetric.

The SpaceX lockup overhang: supply unlike anything the market has seen

SpaceX (SPCX) went public on June 12 at $135 per share, floated only about 5% of its shares — 629 million — and then ran to over $201 within the first week before falling sharply to trade near $111 in late July^[5]. That is a decline of roughly 45% from the peak.

What makes SpaceX unusual is not the volatility — large IPOs are volatile. It is the scale of locked-up supply. The average IPO floats roughly 20% of shares; SpaceX floated about 5%^[5]. The result is that 6.4 billion or more shares could eventually enter the public market through a series of lockup expirations stretching to June 2027^[5]. Renaissance Capital’s senior strategist Matthew Kennedy called it “the longest series of lock-up releases we’ve ever seen”^[5].

The first expiration arrives August 6, when nearly a billion shares become eligible for sale. The next wave hits around August 20, releasing another 455.8 million shares^[5]. Further expirations follow in September and continue through the first anniversary of the IPO. Elon Musk’s stake is not covered by most of these expirations; his shares become eligible in early June 2027, though he has stated he does not plan to sell^[5].

Morningstar analyst Nicolas Owens believes most available shares will come to market because existing holders have low cost bases and long holding periods^[5]. He also suggests the lockup overhang is already part of the story behind the stock’s decline: “It’s conceivable that a good deal of the recent slump in SpaceX stock is precisely in anticipation of the dilution from the lockup”^[5].

There is a second-order effect worth tracking. As SpaceX’s float grows, its weighting in cap-weighted index funds will rise. Morningstar’s Zachary Evens notes that if the float-adjusted market cap triples by the end of September — which is plausible given the scheduled expirations — SpaceX could land between Walmart and Intel in the Nasdaq-100, making it a top-15 holding in funds like the Invesco QQQ Trust^[5]. That means passive funds would be forced buyers, absorbing some of the supply. But Owens does not think that will be enough: “Unless something changes the fundamental story or sentiment — like for the better — the supply from these lockups will outweigh demand even from index funds”^[5].

The question for the broader market is whether the SpaceX unlock absorbs risk appetite that would otherwise flow to new issuance. If a billion shares of a high-profile name hit the market in August and the stock continues to slide, the read-across to other recently listed names — and to IPO demand from the buy side — could be negative. The counter-argument is that SpaceX is a unique situation: no other 2026 IPO has a comparable locked-up float. But uniqueness cuts both ways. The market has no template for how a $1.5 trillion company transitions from 5% float to 25% float over twelve months.

The SEC proposes rescinding Reg NMS’s trade-through rule

On June 11, 2026, the SEC proposed amendments to Regulation NMS that would rescind Rule 611 — the trade-through rule — and Rule 610(e), the prohibition on locking and crossing quotations^[6]. Skadden described it as “one of the most significant changes to U.S. equity market structure since the adoption of Regulation NMS”^[6].

Rule 611, adopted in 2005, requires trading centers — exchanges, ATSs, OTC market makers, and internalizing broker-dealers — to prevent executions at prices worse than protected quotations displayed at other venues. In plain terms, if a better price is available elsewhere, you must route there first^[6]. The SEC’s rationale for rescission rests on three arguments: that modern markets are highly automated and interconnected, making the rule’s routing mandates unnecessary; that Rule 611 has produced market complexity, fragmentation, and a proliferation of complex order types; and that broker-dealers’ duty of best execution would continue to protect investors regardless^[6].

The proposal has notably different implications for different participants. Institutional investors may benefit from greater flexibility to access liquidity, reduce information leakage, and minimize the costs of sourcing liquidity across multiple venues^[6]. Large wholesalers and internalizing broker-dealers could gain room to design routing strategies that weight execution quality factors beyond displayed price^[6]. Smaller exchanges that currently benefit from the protected-quote framework could face reduced order flow^[6].

For retail investors, the picture is more ambiguous. The trade-through rule was designed in part to ensure retail orders received the best displayed prices. Its removal does not eliminate best-execution obligations, but it removes a bright-line standard that made compliance straightforward and auditable. As Skadden notes, broker-dealers “likely will need to reassess their best execution policies and procedures and place greater emphasis on documenting and reviewing routing decisions”^[6]. The shift from a rules-based to a principles-based framework is not inherently harmful — but it does transfer discretion from a regulatory mandate to individual firms, and that is where outcomes will diverge.

The public comment period runs 60 days from Federal Register publication, which occurred June 17^[6]. That places the comment deadline in mid-August 2026. Significant revisions before a final rule are possible.

NYSE tokenized securities: the plumbing is already changing

In parallel with the Reg NMS proposal, the SEC approved a NYSE rule change — filed April 9, 2026, with immediate effectiveness — enabling the exchange to trade securities in tokenized form during the DTC’s tokenization pilot program^[7]. The rule covers Russell 1000 stocks, major ETFs, and Treasury products, and moved into operative status around late May 2026^[7]. The SEC had approved a corresponding Nasdaq proposal earlier^[7].

The Reg NMS rescission and the tokenized securities rule are separate proceedings, but they interact. As Skadden observes, the rescission of Rule 611 would eliminate a market structure requirement that is “particularly difficult to apply in nascent markets that are not interconnected in the same manner as traditional equities markets”^[6]. If tokenized securities trade on venues that are not interconnected through the same SIP feeds and routing infrastructure, enforcing a trade-through rule across them would be operationally complex. Removing that rule in advance smooths the path.

What to watch next

• SpaceX earnings (expected August 4): The company’s first earnings report as a public company arrives two business days before the first lockup expiration^[5]. The combination of fundamental data and immediate selling eligibility is a high-information event. If earnings disappoint, the lockup supply hits a market that is already repricing. If they impress, it may absorb some of the selling pressure.
• SpaceX lockup wave (August 6, August 20, September): The first expiration unlocks nearly a billion shares; the second adds 455.8 million^[5]. Watch the volume and price impact, and whether index fund rebalancing absorbs or amplifies the supply.
• Biotech IPO pricing (August 5–6): Whether Attovia, Braveheart, and Vogenx price within their ranges — and how they trade on day one — is a read on risk appetite for pre-revenue companies.
• Reg NMS comment deadline (mid-August): The 60-day comment window closes. Industry feedback will shape whether the proposal moves toward adoption in its current form or is substantially revised^[6].
• Jersey Mike’s first full week of trading: A 6% first-day decline is not catastrophic, but whether JMKE stabilizes or continues lower will influence sponsor confidence for the next large consumer IPO.

The base-rate read is that August will be a high-volume, high-volatility month for newly listed equities. The interaction between fresh issuance and lockup-driven supply is the variable to watch. When both increase simultaneously, the question is not whether the market can absorb the volume — it usually can — but at what price.